# Step 140 — PC07.01 automated acceptance reconciliation and reduced owner review

2026-10-22. **13 new Chromium tests PASS; reuse 135 .NET + 12 frontend PASS from Step 138.** The owner does not need to replay the technical checklist in Step 139 section 6. Use the short review in section 5 below. **PC07.01: PARTIAL. Inventory before/after: 10 mandatory-gap IDs / three packages.**

## 1. Scope, Git checkpoint and authority

Owner requested reconciliation of the lengthy manual checklist against existing automation, additional necessary browser coverage, and a reduced manual review. This authorizes focused test additions/execution for this follow-up; Step 139's prohibition on new tests described that earlier preparation task. It does not authorize live clinical writes, migrations or restarts.

Read AGENTS.md first. Branch `main`; HEAD `b7fa5d7c12bcecc76a04f44ab40012495238218d`. Working-tree status recorded once: existing Step 138 modifications, new migrations 0086–0088, reports 199–206 and prior test/helpers were present. All preserved. No Git staging, commit, branch change, reset, cleanup or remote operation.

Reused Steps 135/137/138/139 and the established Step 115 authoritative mapping. These establish mandatory data-support obligations and the approved clinical contracts. The inspected mapping does **not** establish a requirement for a human to repeat every boundary, persistence, audit or concurrency assertion. The extensive checklist was a project acceptance approach, not evidence of a specification-mandated manual test for every item. This bounded reconciliation does not determine an external assessor's acceptance policy or accepted certification release. Existing release/source qualifications remain.

Only a new test file, this report and a navigation note in Step 139 are changed. No product source, configuration, schema, deployment or clinical record changed. Headless browser tests use in-memory HTML and block network requests; they do not log into any tenant or create database fixtures.

## 2. Evidence retained and owner results

- Step 138 retained TRX `.tmp/step138/step138-final.trx`: **135 total, 135 passed, zero failed/not executed**. Retained frontend log `.tmp/step138/frontend-final.log`: **12 passed, zero failed/skipped**. Counters re-read; tests not rerun.
- Existing TypeScript PASS and affected-project build evidence remain historical Step 138 evidence, not newly executed results.
- Owner reported **PASS for all four Drug Description checks (A1–A4)** in conversation: compound context/safe display, 300/301 attempt, single-line behavior, Draft/Finalized/correction preservation. Preserve those reports; no repeat requested. Screenshots, individual record IDs/build identity and exact boundary/multiline observations were not supplied with those PASS statements. Do not invent them or call a reported client prevention an observed server rejection. Native normalization and automated server validation are separately identified below.
- Owner states migrations 0086–0088 were already run. This is owner-reported deployment information, not a fresh ledger/hash/application-version verification. Step 139 remains a historical predeployment checkpoint. No migration rerun or API/Web rollout is performed here.

## 3. Checklist-to-evidence reconciliation

Rows follow Step 139 section 6 in order. “Automated PASS” means the named test scope, not a deployed-tenant observation or external certification. Historical evidence is reused without claiming new execution.

| Item | Controlling automated evidence | Remaining owner task |
|---|---|---|
| A1 compound text, separate names, safe display/help | New `DescriptionEditorPreservesCompoundAndIndependentNamesAndEnforcesBrowserBoundary`; six new Details cases; existing `PrescriptionDetailDisplayTests` and Step 138 compound persistence | Already owner-reported PASS; no repeat |
| A2 300/301 units | Existing `Step138DescriptionTests.BoundaryUsesUtf16AndPreservesInternalText`, direct SQL rejection in `LegacyIdentityIsNotEnrichedAndDirectSqlRejectsAboveLimit`; new Chromium 300 accepted/301st typed character prevented | Already reported PASS; no new manual server attempt |
| A3 multiline | Existing `InvalidDescriptionIsRejectedBeforeRepository` separator cases; new Chromium input fill normalization preserves both text segments with a separating space | Already reported PASS; clipboard/OS variations are not newly exercised |
| A4 Draft/finalized/correction and original artifact | Existing `DescriptionTreatmentAndNativeIdentitySurviveFinalizationAndCorrection` for both finalization paths; `PrescriptionDatePrecisionTests` lifecycle/audit cases | Already reported PASS; no lifecycle replay |
| B1 native first/last/OHIP and original attribution | Same Step 138 native-identity lifecycle test; new Details checks separate retained fields and `001234` presentation; existing original-author/permission coverage | Review meaning/presentation once, below |
| B2 legacy snapshots and no live enrichment | Existing `LegacyIdentityIsNotEnrichedAndDirectSqlRejectsAboveLimit`; new Details NULL identity displays Not recorded | No provider-profile edit needed |
| C1 independent long-term intent across entry surfaces | Existing `IndependentIntentOmissionClearAndPastMappingRemainAuditedAndVersioned`, frontend false/null modal test and classification mapping tests; four new Chromium source-control cases | Review clinical wording once; no 3×3 manual state matrix |
| C2 independent treatment/omit/clear | Existing Step 138 prescription lifecycle and wire-contract tests; new Details text/unknown checks | Include in the same wording review |
| C3 Past only from Discontinued; future dates | Existing Step 138 plan assertions, `DiscontinueCannotInventAnEndBeforeAFutureStart` and classification lifecycle evidence | No manual discontinuation or cancellation needed |
| D1 substitution Yes/No/unknown/clear/omission | Existing `OmittedSubstitutionAndExplicitClearHaveDifferentWireContracts` plus prescription persistence/correction; new editor options and six Draft/Finalized Details cases | Include in the same wording review |
| D2 lifecycle/private notes/status | Reuse A4 and accepted V1/V2/V3 plus Step 138 `PrescriptionPrivateNoteTests`/`PrescriptionPrivateNoteWebTests` regression; new Details status cases | No private-note replay |
| E1 applicability independent of legacy type | Existing `ExplicitApplicabilityDoesNotReclassifyLegacyTextAndOmissionPreservesIt`; new rendered allergy controls and production script preserve Contrast | Review clinical wording once |
| E2 conditional DIN/zeroes/no silent erasure | Same SQL/API cases and existing allergy validation tests; new Chromium retains `00123456` during every applicability switch, verifies hidden group for empty unknown and visible for Drug | No manual conflicting save needed |
| E3 persistence/audit/history | Existing Step 138 allergy persistence/omission/clear and `AllergyFieldSqlTests` provenance/audit/rollback assertions | No new clinical save/history creation |
| F1 patient/tenant/role boundaries | Existing `RealHttpPermissionsBothTenantDirectionsOwnershipActorAndInvalidInputAreRejected`, medication denied/foreign-scope tests, allergy scoped-read tests | Confirm visible context once for the short deployed review |
| F2 layout/labels/error retention | New rendered description validation error retains ModelState text; safe Details rendering; browser controls; existing frontend tests | One visual/clinical review below; full Bootstrap layout not certified by fragments |
| F3 stale saves/no automatic retry | Existing prescription/plan RowVersion tests and allergy race tests; frontend `Resolve submits the captured positive token, retains reason on conflict and never refreshes/retries` | No two-session manual replay |
| F4 trusted actor/atomic audit/no extra live writes | Existing Step 138 active-actor checks and mandatory audit failure rollback; `AllergyFieldSqlTests.RequiredAuditFailureRollsBackEveryMutationIncludingBothReplacementDestinations` and prescription audit-fault cases | Automated evidence retained; appearance cannot establish atomicity |

These checks are accepted as automated engineering evidence for this checklist. Remaining visual/clinical observations are outstanding only where not already owner-reported. Unexecuted manual variants are **not required for this reduced engineering pass**; they are not relabelled manual PASS.

## 4. New focused verification and limits

Added `tests/MicroEMR.Api.Tests/Step140BrowserAcceptanceTests.cs`, using the existing transitive Microsoft.Playwright dependency and installed Chromium; no package changes:

- Two tests render the compiled production prescription editor: labels/help, compound and independent inputs, safe encoding, real maxlength behavior, single-line fill normalization, substitution options, validation feedback and unsaved ModelState text.
- Six theory cases render production Details for Draft/Finalized × Yes/No/Not recorded, checking retained first/last/OHIP and treatment/description, safe text rendering and absence of editable controls.
- One test renders the production allergy partial and executes the emitted production allergy script with an isolated form's legacy type selector. Checks all four applicability options, DIN leading zeroes and non-erasure, legacy type independence and conditional group behavior.
- Four theory cases exercise the literal intent/classification selects from standalone Create/Edit, quick-add and edit-modal source, plus the emitted production modal-loading script. Check true/false/unknown independently of all three classifications. These are source-control browser fixtures, **not full Razor rendering or authenticated chart/modal navigation**. Existing persistence tests supply the independent storage evidence.

**Final: 13 passed, zero failed, zero skipped.** TRX `.tmp/step140/step140-browser-final.trx`; log `.tmp/step140-browser-final.log`. Only the new class was run. No SQL-backed tests or full regression suite rerun. The evidence portfolio is 147 retained tests plus 13 new tests, not a single newly executed 160-test run.

Affected test-project build: **PASS, zero errors, six NU1900 vulnerability-metadata warnings**, `.tmp/step140-build.log`. Used existing isolated artifacts to avoid running-service DLL locks. No full solution build, dependency update or restart.

The initial run had seven harness failures: six rendering cases lacked endpoint-routing metadata; one expected CR/LF removal rather than the actual space produced by Chromium fill. Corrected the test harness/expected documented interaction, then reran the new class successfully. No product failure or product fix was inferred. The initial diagnostic result is not final PASS evidence.

```powershell
dotnet build tests/MicroEMR.Api.Tests/MicroEMR.Api.Tests.csproj --no-restore --artifacts-path .tmp/step138/build -v:q
$env:PLAYWRIGHT_BROWSERS_PATH = Join-Path $PWD '.tmp/step116-browsers'
dotnet test tests/MicroEMR.Api.Tests/MicroEMR.Api.Tests.csproj --no-build --no-restore --artifacts-path .tmp/step138/build --filter 'FullyQualifiedName~Step140BrowserAcceptanceTests' --logger 'trx;LogFileName=step140-browser-final.trx' --results-directory .tmp/step140
```

Limitations: no authenticated live-tenant navigation, actual clipboard paste, matching deployed application attestation, Bootstrap modal/layout integration or human clinical-meaning judgment. Tests do not prove external release acceptance or undisclosed workflows. Browser CR/LF normalization is not server rejection and does not approve clinically meaningful shortening. Test input is explicitly synthetic; it is not prescribing advice.

## 5. Replacement owner review — one short read-only pass

**Use this section instead of replaying Step 139 section 6.** Drug Description A1–A4 are already reported PASS. Do not generate additional records or repeat boundary/lifecycle/security/audit tests.

Confirm the intended development tenant/patient context and matching Step 138 application before the review. Migration execution alone does not update API/Web. If application deployment is uncertain, record that prerequisite outstanding; do not run migrations again to resolve it.

- [ ] **Prescription:** on suitable existing editor/Details screens, confirm that separate prescriber first/last/OHIP, Treatment type and Substitution prohibited labels convey the intended meaning, including Not recorded. Check readable layout once. No save/finalize/correction or provider-profile change required.
- [ ] **Medication plan:** confirm Long-term treatment intent and Past medication wording correctly convey the approved independent plan facts, alongside classification. Glance at standalone and chart/modal placement for usability. No Yes/No/Unknown save matrix or discontinue action required.
- [ ] **Allergy:** confirm Drug/Non-drug/Unknown versus Not recorded wording and DIN reconciliation help are clinically understandable and readable. No contradictory save or legacy reclassification required.

Report PASS or the specific wording/layout issue for these three observations. A missing suitable existing screen can remain DEFERRED; do not manufacture clinical records. No screenshots are mandatory for this reduced project review; record the actual observation and available environment/evidence reference. This does not waive evidence an external assessor explicitly requires.

## 6. Status, changed files and next step

**PC07.01 remains PARTIAL. Inventory before/after: 10 mandatory-gap IDs / three packages.** Prior DE09.003 and other closure decisions retained. Drug Description owner PASS is preserved with the evidence qualifications above; no new field-level or whole-parent certification promotion is made solely from these component tests. Q5–Q7 deferred clinical/source features remain unchanged.

Changed files for this follow-up only:

1. `tests/MicroEMR.Api.Tests/Step140BrowserAcceptanceTests.cs` — new focused automated browser acceptance coverage.
2. `docs/certification/207-step140-pc07-01-automated-acceptance-reconciliation.md` — exact mapping, evidence limits, owner PASS preservation and three-item replacement review.
3. `docs/certification/206-step139-pc07-01-deployment-readiness-manual-acceptance.md` — pointer to this replacement; original checkpoint/checklist retained historically.

**Next:** record only the three short owner observations above and reconcile the qualified implemented slices. Resolve deployment attestation separately if still missing. Do not reopen Q5–Q7, repeat accepted Drug Description/private-note checks, rerun migrations or claim external certification. Final review: only the listed test/docs changes added; no product changes or live clinical actions.
